Novavax Inc (NVAX) Stock AnalysisNVAXNovavax Inc

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Novavax Inc is a good buy right now due to its recent price increase of 21.89% over the last 5 days and a current price of $12.75, which is significantly above its 200-day simple moving average of $9.015. The stock's RSI is at 71.683, indicating strong momentum, while the forward P/E ratio is an attractive 2.58, suggesting potential for future earnings growth. However, the main risk is its negative net income margin of -94.16% in Q2 2026, which highlights ongoing profitability challenges.

7 analysts cover NVAX: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 10.50.